Pharmacogenomics and personalized medicine
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Major Dutch academic medical center strong in complement immunology, 3D bioprinting, stroke research, and translational medicine across 146 H2020 projects.
“Participation in U-PGx (Ubiquitous Pharmacogenomics), OPERAM for elderly polypharmacy, and cystic fibrosis precision therapy (PRO-CF-MED).”
NL146 projects - ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH
Stuttgart-based clinical pharmacology research institute specializing in pharmacogenomics, digital health validation, and pediatric clinical trial networks.
“U-PGx aims to make pharmacogenomic data actionable for treatment optimization across European healthcare systems.”
PrimaryDE4 projects - CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
Italian national cancer research institute contributing clinical oncology, pharmacogenomics, and biobanking expertise to European precision medicine consortia.
“U-PGx (EUR 875K) focused on making pharmacogenomic data actionable for effective treatment optimization.”
PrimaryIT3 projects